. Moya-Horno I, Viteri S, Karachaliou N, et al. Combination of immunotherapy with targeted therapies in advanced non-small cell lung cancer (NSCLC)[J]. Therapeutic Advances in Medical Oncology, 2018, 10: 1758834017745012.
. Bruno D, Dowlati A. Immunotherapy in EGFR mutant non-small cell lung cancer: when, who and how?[J]. Translational Lung Cancer Research, 2019, 8(5): 710.
. Spigel D R, Reynolds C, Waterhouse D, et al. Phase 1/2 study of the safety and tolerability of nivolumab plus crizotinib for the first-line treatment of anaplastic lymphoma kinase translocation—positive advanced non–small cell lung cancer (CheckMate 370)[J]. Journal of Thoracic Oncology, 2018, 13(5): 682-688.
. Saito H, Fukuhara T, Furuya N, et al. Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial[J]. The Lancet Oncology, 2019, 20(5): 625-635.
. Soo R A, Han J Y, Dafni U, et al. A randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations: the European Thoracic Oncology Platform (ETOP 10-16) BOOSTER trial[J]. Annals of Oncology, 2022, 33(2): 181-192.
. Boyer M, Şendur M A N, Rodríguez-Abreu D, et al. Pembrolizumab plus ipilimumab or placebo for metastatic non–small-cell lung cancer with PD-L1 tumor proportion score≥ 50%: randomized, double-blind phase III KEYNOTE-598 study[J]. Journal of Clinical Oncology, 2021, 39(21): 2327-2338.
. Peters S, Ramalingam S S, Paz-Ares L, et al. Nivolumab (NIVO)+ low-dose ipilimumab (IPI) vs platinum-doublet chemotherapy (chemo) as first-line (1L) treatment (tx) for advanced non-small cell lung cancer (NSCLC): CheckMate 227 part 1 final analysis[J]. Annals of Oncology, 2019, 30: v913-v914.